Neuracle Science Co., Ltd. · Biologic · Phase 1/2
ActiveTherapeuticStronger sources
Population
Adults · 19–70 years
Steroid-treated persistent unilateral SSNHL
Evidence
trial
Confidence
92%
Indications
Hearing LossSensorineural Hearing LossSudden Sensorineural Hearing LossCochlear Synaptopathy
